natgillin/translations-raw huggingface dataset:
A compound according to any one of claims 1 to 6, or a composition according to claim 8, for use in the prevention and/or treatment of airway diseases selected from the group consisting of pulmonary fibrosis, emphysema, chronic bronchitis, asthma, fibrosis, pneumonia, cytsis fibrosis, chronic obstructive pulmonary disease (COPD), bronchitis rhinitis, and respiratory distress syndrome; preferably asthma or COPD. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili pripravak u skladu s patentnim zahtjevom $, za uporabu u prevenciji i/ili liječenju bolesti dišnih puteva izabranih iz skupine koja se sastoji od plućne fibroze, emfizema, kroničnog bronhitisa, astme, fibroze, upale pluća, cistične fibroze, kronične opstruktivne plućne bolesti (COPD), bronhitisa, rinitisa i sindrom respiratornog distresa; poželjno astme ili COPD.
The reaction was stirred at 80°C overnight. 
Reakcija se miješa na 80*C preko noći.
A composition according to claim 1, wherein component (A) is 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbomene-5-yl)amide and component (B) is selected from azoxystrobin and picoxystrobin. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-diklorometiliden-benzonorbornen-5- iDamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) mandipropamid.
the position of the two points, with respect to the propulsive element, is varied. 
položaj dvije točke u odnosu na propulzivni element varira.
A compound according to Claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment of a colorectal cancer, a head and neck cancer, a pancreatic cancer, a breast cancer, a gastric cancer, a bladder cancer, a vulvar cancer, a leukemia, a lymphoma, a melanoma, a renal cell carcinoma, an ovarian cancer, a brain cancer, an osteosarcoma, or a lung cancer. 
4. Spoj u skladu s patentnim zahtjevom I, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenje kolorektalnog rak, raka glave i vrata, raka gušterače, raka dojke, raka želuca, raka mokraćnog mjehura, raka stidnice, leukemije, limfoma, melanoma, karcinoma bubrežnih stanica, raka jajnika, raka na mozgu, osteosarkoma ili raka pluća.
R and R' are each independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; wherein R12, R16, R19 and R17 are as defined for R2, R6, R9 and R7 respectively; wherein R" is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, N(H), NMe and/or aromatic rings, e.g. benzene or pyridine, which rings are optionally substituted; 
R" jeili Hili R ili, tamo gdje Q je O, SO;M, gdje M je metalni kation; svaki od R i R' je neovisno odabran od opcijski supstituiranih sljedećih skupina: C,.palkil, C32oheterociklil i Cs.20aril, i prema potrebi u odnosu na skupinu NRR', R 1 R' zajedno s atomom dušika na kojega su priključeni, tvore opcijski supstituirani 4-člani, 5-člani, 6-člami ili 7-člani heterociklički prsten; dok su R!", R', R"? i R'" kao što su definirani za redom odgovarajuće R?, R*, RiR! gdje R" je C3.palkilen- skupina koja može biti prekinuta s jednim ili više heteroatoma, primjerice O, S, N(H), NME i/ili aromatskim prstenima, primjerice benzen ili piridina, čiji su prsteni opcijski supstituirani;
The aerosol generating means used in the invention is usually located no more than about 60 mm, preferably no more than 30 mm, most preferably no more than 15 mm from the lighting end of the fuel element. 
Sredstvo za generiranje aerosola se obično nalazi ne više od oko 60 mm, poželjno ne više od 30 mm, najpoželjnije ne više od 15 mm od kraja za paljenje gorivog elementa.
4 shows a schematic for another variant of the circuit in FIG. 2 
prikazuje shemu za još jednu varijantu kruga sa slike 2.
The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 8.6, 11.3, 13.1, 15.3, 17.3, 20.5, 22.7, 23.6, 26.3 and 31.4 degrees 2θ. 
Čvrsti oblik u skladu s patentnim zahtjevom 1, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu s maksimumima na otprilike 8,6, 11,3, 13,1, 15,3, 17,3, 20,5, 22.7, 23,6, 26,3 131,4 220.
The pharmaceutical composition of claim 3, wherein said crystalline form is characterized by an X-ray powder diffraction pattern having peaks at 6.35, 12.70, 19.10 and 20.50 degrees 2θ, wherein the pattern is obtained from a copper radiation source (Cu-Ka, 40 kV, 4 mA); a melting point of 168-171 °C; or the differential scanning calorimetry thermogram shown in FIG. 
Farmaceutska kompozicija za uporabu prema patentnom zahtjevu 3, pri čemu je navedeni kristalni oblik naznačen (i) rendgenskim difraktogramom praha koji ima pikove na 6,35, 12,70, 19,10 1 20,0 stupnjeva 20, pri čemu je difraktogram dobiven od izvora zračenja bakra (Cu-Ka 40 kV, 4 mA); (1i) točkom topljenja od 168-171?C; ili (ili) termogramom difrencijalne skenirajuće kalorimetrije prikazanim na SL.
The method of claim 4 where the insomnia is characterized by difficulties in sleep onset or sleep maintenance or both. 
time što je za nesanicu karakteristična poteškoća u počinjanju spavanja ili održavanju spavanja ili oboje. 7.
The method according to claim 1, wherein R7 represents linear or branched (C1-C6)alkyl, linear or branched (C2-C6)alkenyl, linear or branched (C2-C6)alkynyl, aryl, or heteroaryl. 
Spojevi u skladu s patentnim zahtjevom 1 naznačeni time, da R7 predstavlja ravnu ili razgrananu (C1-C6)alkilnu skupinu, ravnu ili razgrananu (C2-C6)alkenilnu skupinu, ravnu ili razgrananu (C2-C6)alkinilnu skupinu, arilnu ili heteroarilnu skupinu.
Rd and Re, are chosen independently from the group consisting of hydrogen, hydroxy, methyl, C1-C4 alkoxy or together with the pertaining C-atoms represent 1,3-dioxolane ring which can be additionally alkyl or alkenyl mono or di-substituted; and Rj is chosen from the group consisting of hydrogen and chlorine. 
Rd i Re se neovisno bira iz skupine koju čine vodik, hidroksi, C1-4alkoksi, ili, zajedno s pripadajućim C-atomima, predstavlja 1,3-dioksolanski prsten, koji može biti daljnje mono- ili disupstituiran s alkilom ili alkenilom; i Rj se bira iz skupine koju čine vodik i klor;
A method of preparing an oligonucleotide of formula (I), 
PATENTNI ZAHTJEVI Postupak pripreme oligonukleotida formule (1),
The pharmaceutical composition of claim 5, wherein the compound of Formula (I') is one or more of the following compounds: 
Spoj formule (T) iz patentnog zahtjeva 5 za njegovu primjenu prema patentnom zahtjevu 5, pri čemu je navedeni spoj jedno ili više od sljedećih spojeva:
is selected from 1H-pyrrolo[2,3-b]pyridin-3-yl; 1H-indol-3-yl optionally substituted with 1 to 2 radicals independently selected from halo, methyl and methoxy; and phenyl optionally substituted with 1 to 2 radicals independently selected from methyl, halo and hydroxy; 
se bira niza koji čine 1H-pirolo[2,3-b]piridin-3-il; 1H-indol-3-il po izboru supstituiran s 1 do 2 radikala koji se neovisno biraju iz niza koji čine halo, metil i metoksi; i fenil po izboru supstituiran s 1 do 2 radikala koji se neovisno biraju iz niza koji čine metil, halo i hidroksi;
travels independently over the bed of the body of water on a caterpillar chassis, 
se neovisno kreće preko dna površine vode na posebnoj šasiji s gusjenicama (10),
The method of claim 9, wherein the cell comprises a single vector comprising a nucleic acid encoding the amino acid sequence of SEQ ID NO: 3 and a nucleic acid encoding the amino acid sequence of SEQ ID NO: 4. 
Postupak prema zahtjevu 9, naznačen time da stanica sadrži jedan vektor koji sadrži nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 3 i nukleinsku kiselinu koja enkodira amino kiselinsku sekvencu SEQ ID NO: 4.
agglomerating the ground mixture, 
- < sakupljanje samljevene mješavine,
A compound of formula VI: or a salt thereof, wherein: 
Spoj, naznačen time, da ima formulu VI:
It should be further noted that the scope of the present invention is determined only by the scope of the appended claims. A communication method comprising: generating resource assignment information including a plurality of bits that indicate activation or deactivation statuses of respective downlink component carriers, the downlink component carriers being secondary downlink component carriers added to a primary component carrier which is always activated, each downlink component carrier corresponding to one bit included in the plurality of bits, and the one bit indicating that a corresponding downlink component carrier is to be activated or deactivated, wherein when any one bit of the plurality of bits indicates that its corresponding downlink component carrier is to be activated, the plurality of bits jointly indicate the activation or the deactivation statuses and a sounding reference signal, SRS, transmission request; 
Komunikacijska metoda sadržeći: prijem informacija o raspoređivanju resursa, uključujući pluralitet bitova koji pokazuju statuse aktivacije ili deaktivacije odgovarajućih nosača komponenti silazne veze, nosači komponenti silazne veze su sekundarni nosači komponenti silazne veze dodani primarnom nosaču komponenti koji je uvijek aktiviran, svaki nosač komponenti silazne veze odgovara jednom bitu koji je uključen u pluralitet bitova, i taj jedan bit pokazuje da li se treba aktivirati ili deaktivirati odgovarajući nosač komponenti silazne veze, naznačeno time da kad bilo koji bit među pluralitetom bitova ukazuje da treba aktivirati odgovarajući sekundarni nosač komponenti, pluralitet bitova dalje označava zahtjev za prijenos sondirajućeg referentnog signala, SRS; aktivaciju ili deaktivaciju svakog od nosača komponenti silazne veze sukladno informacijama o raspoređivanju resursa; i prijenos SRS prijenosa na aktiviranim sekundarnim nosačima komponenti.
The combined extracts were dried (Na2C03), filtered and evaporated to give the title compound as an oil (30 g), sufficiently pure for further use. 
Spojeni ekstrakli se suše (Na,CO;), filtriraju 1 ispare lako da se dobiva naslovni spoj u obliku ulja (60 g), koje je zadovoljavajuće čisto za daljnju uporabu.
Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, or an optionally substituted unsaturated fused heterobicyclic ring wherein Y is linked to the heterocyclic ring of the fused heterobicyclic ring; or 
Prsten A je opciono supstituirani benzenov prsten, i Prsten B je opciono supstituirani nezasićeni monociklični heterociklični prsten, ili opciono supstituirani nezasićeni fuzirani heterobiciklični prsten, pri čemu je Y povezan za heterociklični prsten fuziranog heterobicikličnog prstena; ili
The polypeptide of any one of paragraphs 1-3 wherein the polypeptide elicits a protective immune response in a mammalian host against strains of C.difficile. 
Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što polipeptid izaziva zaštitni imunosni odgovor kod sisavačkog domaćina protiv sojeva bakterije C. difficile.
QS water, wherein said liquid pharmaceutical composition is formulated in the form of a nasal spray or nasal drops. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što je navedeni pripravak formuliran kao tekuća formulacija u obliku nazalnog spreja ili nazalnih kapi.
The pharmaceutical composition as claimed in claim 1 for use in a method of treatment or prevention of cancer characterized by expression of the tumor-associated antigen according to claim 1, in which the antibody is a monoclonal, chimeric or humanized antibody, or is a fragment of an antibody. 
Farmaceutska kompozicija prema patentnom zahtjevu 1 za uporabu u postupku za liječenje ili prevenciju kancera naznačenog ekspresijom antigena povezanog sa tumorom prema patentnom zahtjevu 1, gdje je antitijelo monoklonalno, himerno ili humanizirano antitijelo, 1li je fragment antitijela.
The method of claim 1, wherein the constant domains comprise Igk-C and Igλ-C of murine origin, and wherein the structural loop regions of the Igk-C and Igλ-C domains comprise amino acids 8 to 20, amino acids 26 to 36, amino acids 43 to 79, amino acids 83 to 85, amino acids 90 to 101, amino acids 108 to 116 and amino acids 122 to 125, wherein the numbering of the amino acid sequences of the immunoglobulins is according to the IMGT numbering scheme. 
Postupak u skladu sa zahtjevom 19 ili 20, naznačen time, da imunoglobulin obuhvaća neko od područja petlje Igkapa ili Ig-lambda koja obuhvaćaju modifikaciju u jednom aminokiselinskom položaju unutar aminokiselinske sekvence izabrane iz skupine koju čine aminokiseline 8 do 20, aminokiseline 26 do 36, aminokiseline 43 do 79, aminokiseline 83 do 85, aminokiseline 90 do 101, aminokiseline 108 do 116 i aminokiseline 122 do 125, pri čemu je numeriranje prema IMGT.
The compound for use according to claim 6, wherein said compound is for administration in the form of a transdermal patch, ointment, lotion, cream, or gel. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je navedeni spoj za davanje u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
Sometimes symptoms even worsen during the first weeks of treatment. 
Ponekad se, tijekom prvih tjedana terapije, simptomi čak pogoršavaju.
The piercer 11 has again been provided with a resilient collar 25 working as described above with reference to Figures 2a-2c. 
Bušilo 11 ponovno ima elastičan prsten 25, koji djeluje kako je opisano gore u vezi sa slikama 2a-2c.
A lock as claimed in claim 8, characterised in that the end of the slide is housed in a slotted hole (52) through which screws pass for securing the defender (42) to the lock. 
Brava u skladu s patentnim zahtjevom 8, naznačena time što je završetak kliznog elementa (44) smješten u izduženu rupu (52) kroz koju prolaze vijci koji učvršćuju zaštitni element (42) na bravu.
5-40% by weight on a dry weight basis of a pharmaceutically acceptable lactose; 
od 20 do 25 masenih postotaka na bazi suhe mase farmaceutski prihvatljive laktoze;
Subcutaneous IG infusion can be facilitated by gravity, pump infusion or injection of a full 20-30 gram dose. Generally, for infusions intravenous infusion pumps can be employed. 
Kombinacija prema zahtjevu 1, naznačena time da je IG u pripravku formuliran za supkutanu infuziju gravitacijom, pumpnom infuzijom ili ubrizgavanjem u količini koja je 20 do 30 grama.
The vaccine for use according to claim 1 and claims dependent thereto, or according to claim 3 and claims dependent thereto, wherein the vaccine includes a histidine buffer or a phosphate buffer. 
Cjepivo, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, te patentnim zahtjevima ovisnim o njemu, ili u skladu s patentnim zahtjevom 3 i patentnim zahtjevima ovisnim o njemu, naznačeno time što cjepivo sadrži histidinski pufer ili fosfatni pufer.
The inner part may be integrated with the first and second parts by means of inject-moulding. 
Na taj način može unutarnji dio biti izliven oko prvog i drugog dijela.
The method according to claim 1, wherein the number of oil droplets having a size of >1.2 um in the first emulsion is 5×1011/ml or less. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da je broj kapljica ulja veličine > 1.2 um u prvoj emulziji 5 x 10' /mlili manji.
the first fragment is a toxin A repeating domain fragment and comprises at least 100 amino acids; 
prvi fragment je fragment ponavljajuće domene toksina A iz bakterije C. difficile;
a hybridoma capable of producing the antibody of any one of claims 1 to 14 and 
Hibridom sposoban proizvesti protutijelo sukladno patentnom zahtjevu 1.
Compounds according to claim 1, wherein R1 represents a linear or branched (C1-C6)alkyl group or a halogen atom. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da R1 predstavlja ravnu ili razgrananu (C1-C6)alkilnu skupinu ili atom halogena.
The pharmaceutical composition of claim 3 for use in a method of improving cognition in a subject suffering from Alzheimer's disease. 
Farmaceutski sastav iz patentnog zahtjeva 3 za uporabu u metodi poboljšanja kognicije kod subjekta koji pati od Alzheimerove bolesti.
From these tests it appears, as resulting from figure 2, that FLD lines of the Forming Limit Diagram relating to two different steel strips can be overlapped, thus confirming that the strip according to the invention can suitably replace a cold rolled one. 
Iz ovih testova izgleda da, kao što proizilazi 17 slike 2, da FLD linije dijagrama granice formiranja povezanog sa dvije različite čelične trake mogu se preklapati, čime se potvrđuje da traka prema izumu može pogodno zamijeniti hladno valjanu traku.
Application Protocol Interface (API) 
(API (Položaji igrača)
According to the example of the figures, the apparatus 1 comprises a door 4 which extends from the first to the last level of the magazine 3, wherein one cell of each level is notional, and wherein the movement system 5 is capable of rotating a single level at a time; in this way, when the apparatus 1 is in the rest phase, the five notional cells are at the door 4, and therefore if the door 4 is opened it is not possible to access any blood bag; when an operator sends to the apparatus 1 a request for loading or unloading a blood bag, the processing system 7 rotates one of the levels of the magazine 3 and brings one of its cells to the door so that the operator can insert or withdraw the blood bag. 
U skladu s primjerom koji je na slikama, ovaj uređaj 1 ima vrata 4 koja se prostiru od prvog do posljednjeg nivoa spremnika 3, pri čemu je po jedna ćelija iz svakog nivoa lažna ćelija i pri čemu sustav za pomicanje 5 može rotirati samo na jednom nivou u isto vrijeme; na taj način, kada je ovaj urcđaj 1 u fazi mirovanja, pet lažnih ćelija sc nalazi na vratima 4, i stoga ako se vrata otvore nije moguć pristup nijednoj vrećici krvi, kada operator pošalje uređaju zahtjev za stavljanje vrećica krvi ili za vađenje vrećica krvi, sustav za obradu 7 rotira jedan od nivoa spremnika 3 i dovede jednu od svojih ćelija na vrata, tako da operator može umetnuti ili izvaditi vrećicu krvi.
administering about 8 mg of dexamethasone on days two, three and four. 
HR P20140759 T1 d) oko 8 mg deksametazona na dane dva, tri 1 četiri.
The method of claim 1, wherein the endogenous 11-cis retinal deficiency is associated with Retinitis Pigmentosa (RP), Leber Congenital Amaurosis (LCA), Retinitis Punctata Albesciens, Congenital Stationary Night Blindness, Fundus Albipunctatus, Age-Related Macular Degeneration, loss of night vision or contrast sensitivity. 
Upotreba iz patentnog zahtjeva 17 ili 18, naznačena time, da je deficijencija endogenog 11-cis-retinala povezana sa senilnom makularnom degeneracijom, Leberovom kongenitalnim amaurozom (LCA), retinitis punctata albesciens, kongenitalnim stacionarnim noćnim sljepilom ili fundus albipunctatus.
The composition according to claim 20, which is a vaccine against a disease caused by N. meningitidis. 
Pripravak u skladu s patentnim zahtjevom 20, naznačen time što je cjepivo namijenjeno protiv bolesti koju uzrokuje bakterija N. meningitidis.
The antibody of claim 9, wherein at least 20% of the oligosaccharides in the Fe region of said polypeptide are bisected, nonfucosylated. 
Antitijelo u skladu sa zahtjevom 9, naznačeno time, da najmanje 20% oligosaharida u Fc regiji navedenog polipeptida je dvogekcijsko, ne-fukozilirano.
a variable light chain having the amino acid sequence of hBRCA84D-2 VL (SEQ ID NO: 89); 
varijabilnu domenu lakog lanca koja ima aminokiselinski slijed SEQ ID NO: 89;
A method of monitoring the progression of a platelet-related disorder comprising the steps of determining the level of at least one microRNA selected from the group consisting of miR-126, miR-197, miR-223, miR-24 and miR-21 in a plasma or serum sample obtained from an individual at a first time point, determining the level of at least one microRNA selected from the group consisting of miR-126, miR-197, miR-223, miR-24 and miR-21 in a plasma or serum sample obtained from an individual at a second time point, and comparing the determined levels in the individual at the first and second time points. 
Postupak praćenja tijeka poremećaja vezanog uz trombocite, a koji obuhvaća korake određivanja razine barem jedne mikroRNA odabrane iz skupine koju čine miR-126, miR-197, miR-223, miR-24 i miR-21, u uzorku plazme ili seruma dobivenog od pojedinca u prvoj vremenskoj točki, određivanja razine barem jedne mikroRNA odabrane iz skupine koju čine miR-126, miR-197, miR-223, miR-24 i miR-21, u uzorku plazme ili seruma dobivenog od pojedinca u drugoj vremenskoj točki, i usporedbe dobivenih vrijednosti u pojedinca u prvoj i drugj vremenu.
A pharmaceutical composition comprising a ddRNAi agent according to any one of claims 1 to 7 or a ddRNAi expression cassette according to claim 8 or a ddRNAi expression construct according to claim 9 and a pharmaceutically acceptable carrier or diluent. 
Farmaceutski sastav koja sadrži ddRNKi agens prema bilo kojem od patentnih zahtjeva od 1 do 8 ili ddRNK ekspresijsku kasetu prema patentnom zahtjevu 9 ili ddRNKi ekspresijski konstrukt prema patentnom zahtjevu 10 i farmaceutski prihvatljiv nosač ili razrjeđivač.
contacting the deasphalted oil fraction and hydrogen in the presence of the second hydrocracking catalyst at conditions of temperature and pressure to crack at least a portion of the deasphalted oil; and recovering the second stage effluent from the second reactor, and wherein the fractionating comprises: 
dovođenje deasfaltirane uljne frakcije i vodika u prisutnosti drugog katalizatora za hidrokrekiranje pod određenim uvjetima temperature i tlaka da bi se razbio barem dio deasfaltiranog ulja; te obnavljanje efluenta iz drugog stupnja iz drugog reaktora, i pri čemu frakcioniranje obuhvaća: razdvajanje efluenta prvog i drugog stupnja u visokotlačnom visokotemperaturnom separatoru (40) radi dobivanja proizvoda plinovite faze i proizvoda tekuće faze;
A smoking article was constructed in accordance with the embodiment of Figure 1. 
Cigaretni substitut konstruiran je prema realizaciji sa slike 1.
Such tanks can hold, sometimes, on the order of 100 or more gallons of water. 
Takav spremnik može, ponekad, sadržati oko 400 ili i više litara vode.
Vector comprising a nucleic acid molecule according to claim 7. 
Vektor, naznačen time, da obuhvaća molekulu nukleinske kiseline prema zahtjevu 7.
reacting an intermediate of formula (VII) with lithium aluminium hydride in a suitable solvent, with the formation of a compound of formula (I), wherein s is 1, herein referred to as compounds of formula (I-d) 
€) reakciju međuprodukta formule (VII) sa litij aluminij hidridom u pogodnom otapalu, uz stvaranje spoja formule (D), pri čemu s je 1, ovdje se nazivaju spojevi formule (I-d).
Those weeds include but are not limited to the following plant species: 
Ovi korovi obuhvaćaju, ali bez ograničenja na, slijedeće biljne vrste:
The method of E 36, wherein the antagonist is a monoclonal antibody or a monoclonal antibody fragment. 
Antagonist za uporabu u skladu sa zahtjevom 36, naznačen time, da antagonist je monoklonsko antitijelo ili fragment monoklonskog antitijela.
forming a biphasic composition comprising (i) a first organic phase, and (ii) an alcoholic-caustic phase containing the trans-(-)A9-tetrahydrocannabinol and/or the trans-(+)-A9-tetrahydrocannabinol; 
formiranje bifaznog sastava koji sadrži (i) prvu organsku fazu, i (ii) alkoholno-kaustičnu fazu koja sadrži trans-(-)A9-tetrahidrokanabinol i/ili trans-(+)-A9-tetrahidrokanabinol;
The apparatus of any one of claims 7 to 8, wherein the chemical application means (6) comprises an injector, a sprinkler, a dispenser by weight, piping, or a combination thereof. 
Sustav prema zahtjevu 1, naznačen time što sredstvo za kemijsku primjenu (6) obuhvaća injektor, prskalicu, dozator prema težini, cjevovod ili njihovu kombinaciju.
Conveniently, the compounds of the invention are administered in a unit dosage form containing said compounds in an amount of about 0.01 to 100 mg. 
Ukoliko je to prikladno, spoj izuma se može davati u doznoj jedinici koja sadrži rečene spojeve u količini od 0.01 do 100 mg.